LCG
TARS icon

Lisanti Capital Growth’s Tarsus Pharmaceuticals TARS Stock Holding History

Lisanti Capital Growth’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,815
Closed -$2.93M – 145
2026
Q1 		$2.93M Sell
41,815
-22,526
-35% -$1.57M 0.74% 59
2025
Q4 		$5.27M Buy
64,341
+21,330
+50% +$1.59M 1.25% 29
2025
Q3 		$2.56M Sell
43,011
-32,514
-43% -$1.6M 0.63% 72
2025
Q2 		$3.06M Buy
75,525
+5,345
+8% +$241K 0.85% 53
2025
Q1 		$3.61M Sell
70,180
-26,755
-28% -$1.32M 1.07% 40
2024
Q4 		$5.37M Buy
96,935
+57,090
+143% +$2.59M 1.29% 30
2024
Q3 		$1.31M Buy
+39,845
New +$1.12M 0.33% 97

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lisanti Capital Growth's TARS Position: Q2 2026 in Review

Lisanti Capital Growth sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 41,815 shares — an estimated $2.93M sold.

Lisanti Capital Growth first reported a position in TARS in Q3 2024 and held it in 7 quarters. The position peaked at $5.37M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Lisanti Capital Growth reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Lisanti Capital Growth sold 41,815 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.93M.
  • Lisanti Capital Growth first reported a position in Tarsus Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • Lisanti Capital Growth's Tarsus Pharmaceuticals position peaked at $5.37M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.